Plasma lipoprotein(a) levels and LDL-cholesterol lowering response to statin therapy in patients with heterozygous familial hypercholesterolemia

Annals of Clinical and Laboratory Science

Volumn 36, Issue 3, 2006, Pages 353-355

  Miltiadous, George ^a   Saougos, Vasilios ^a   Cariolou, Marios ^b   Elisaf, Moses S ^a,c  

^a UNIVERSITY OF IOANNINA   (Greece)

^b CYPRUS INSTITUTE OF NEUROLOGY AND GENETICS   (Cyprus)

^c UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Familial hypercholesterolemia; Lipoprotein(a); Statins

Indexed keywords

ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; TRIACYLGLYCEROL;

ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CORRELATION ANALYSIS; DRUG EFFECT; DRUG EFFICACY; ENVIRONMENTAL FACTOR; FAMILIAL HYPERCHOLESTEROLEMIA; GENE MUTATION; HETEROZYGOSITY; HUMAN; ISCHEMIC HEART DISEASE; LIPOPROTEIN BLOOD LEVEL; NEPHROTIC SYNDROME; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL;

ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, LDL; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPOPROTEINEMIA TYPE II; LIPOPROTEIN(A); STATISTICS, NONPARAMETRIC;

EID: 33748251332     PISSN: 00917370     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. Kraft HG, Lingenhel A, Raal FJ, Hohenegger M, Utermann G. Lipoprotein(a) in homozygous familial hypercholesterolaemia. Arterioscler Thromb Vasc Biol 2000;20:522-528.
2. Elisaf M, Bairaktari E, Siamopoulos C. Lp(a) levels in Greek patients with heterozygous familial hypercholesterolemia. Int J Cardiol 1996;53:314-316.
3. Goldstein JL, Brown MS. Familial hypercholesterolemia. In: The Metabolic Basis of Inherited Disease, 7th ed, (Stanbury JB, Wyngaarden JB, Fredrickson DS, Eds), McGraw-Hill, New York, 1992; pp 1215-1250.
4. Nassir F, Bonen DK, Davidson NO. Apolipoprotein (a) synthesis and secretion from hepatoma cells is coupled to triglyceride synthesis and secretion. J Biol Chem 1998;273:17793-17800.
5. Shames DM, Havel RJ. De novo production of low density lipoprotein: fact or fancy. J Lipid Res 1991;32: 1099-1112.
6. Betteridge DJ, Broome K, Durrington PN. Scientific steering committee on behalf of the Simon Broome Register Group. Mortality in treated heterozygous familial hypercholesterolaemia: implications for clinical management. Atherosclerosis 1999;3:61-67.
7. Miltiadous G, Xenophontos S, Bairaktari E, Ganotakis M, Cariolou M, Elisaf M. Genetic and environmental factors affecting the response to statin therapy in patients with molecularly defined familial hypercholesterolaemia. Pharmacogenet Genomics 2005;15:219-225.
8. Kronenberg F, Lingenhel A, Lhotta K, Rantner B, Kronenberg M, Konig P, Thiery J, Koch M, von Eckardstein A, Dieplinger H. Lipoprotein (a)- and low-density lipoprotein-derived cholesterol in nephrotic syndrome: Impact on lipid-lowering therapy? Kidney Int 2004;66:348-354.
9. Hobbs HH, Russell DW, Brown MS, Goldstein JL. The LDL receptor locus in familial hypercholesterolemia: Mutational analysis of a membrane protein. Annu Rev Genet 1990;24:133-170.